Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

BACKGROUND: Enhanced phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the key adaptive changes accounting for epidermal growth factor receptor (EGFR) inhibitor-resistant growth in head and neck squamous cell carcinoma (HNSCC). We designed a phase II clinica...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Massarelli, E., Lin, H., Ginsberg, L. E., Tran, H. T., Lee, J. J., Canales, J. R., Williams, M. D., Blumenschein, G. R., Lu, C., Heymach, J. V., Kies, M. S., Papadimitrakopoulou, V.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855241/
https://ncbi.nlm.nih.gov/pubmed/26025965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv194
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller